Microbiota-Driven Tonic Interferon Signals in Lung Stromal Cells Protect from Influenza Virus Infection.
Animals
Anti-Bacterial Agents
/ pharmacology
Bone Marrow Cells
/ cytology
Cell Line
Chimera
/ immunology
Epithelial Cells
/ immunology
Fecal Microbiota Transplantation
Gene Expression Regulation, Viral
/ immunology
Hematopoietic Stem Cells
/ immunology
Humans
Influenza A virus
/ growth & development
Influenza, Human
/ drug therapy
Interferon Type I
/ metabolism
Leukocyte Common Antigens
/ genetics
Lung
/ drug effects
Mice
Mice, Inbred C57BL
Mice, Knockout
Microbiota
/ immunology
RNA-Seq
Receptor, Interferon alpha-beta
/ genetics
Stromal Cells
/ immunology
anti-viral protection
antibiotics
gut
influenza
lung
microbiota
tonic IFN signaling
type I interferon (IFN)
Journal
Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691
Informations de publication
Date de publication:
02 07 2019
02 07 2019
Historique:
received:
02
08
2018
revised:
10
05
2019
accepted:
29
05
2019
entrez:
4
7
2019
pubmed:
4
7
2019
medline:
28
8
2020
Statut:
ppublish
Résumé
Type I interferon (IFNα/β) pathways are fine-tuned to elicit antiviral protection while minimizing immunopathology; however, the initiating stimuli, target tissues, and underlying mechanisms are unclear. Using models of physiological and dysregulated IFNα/β receptor (IFNAR1) surface expression, we show here that IFNAR1-dependent signals set the steady-state IFN signature in both hematopoietic and stromal cells. Increased IFNAR1 levels promote a lung environment refractory to early influenza virus replication by elevating the baseline interferon signature. Commensal microbiota drive the IFN signature specifically in lung stroma, as shown by antibiotic treatment and fecal transplantation. Bone marrow chimera experiments identify lung stromal cells as crucially important for early antiviral immunity and stroma-immune cell interaction for late antiviral resistance. We propose that the microbiota-driven interferon signature in lung epithelia impedes early virus replication and that IFNAR1 surface levels fine-tune this signature. Our findings highlight the interplay between bacterial and viral exposure, with important implications for antibiotic use.
Identifiants
pubmed: 31269444
pii: S2211-1247(19)30744-2
doi: 10.1016/j.celrep.2019.05.105
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Interferon Type I
0
Receptor, Interferon alpha-beta
156986-95-7
Leukocyte Common Antigens
EC 3.1.3.48
Ptprc protein, mouse
EC 3.1.3.48
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
245-256.e4Subventions
Organisme : Cancer Research UK
ID : FC001206
Pays : United Kingdom
Organisme : Wellcome Trust
ID : FC001206
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_U117597139
Pays : United Kingdom
Organisme : Medical Research Council
ID : FC001206
Pays : United Kingdom
Informations de copyright
Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.